The development and testing of a vaccine for the prevention of infectious bovine keratoconjunctivitis
DOI:
https://doi.org/10.21423/aabppro19965986Keywords:
protein cytotoxin, Moraxella bovis, concentrated, vaccine trial, efficacy, toxicityAbstract
We have purified, concentrated and stabilized the protein cytotoxin from Moraxella bovis. The toxin is concentrated on a filter with a 500,000 kDa molecular weight cut off. Small proteins are removed by extensive diafiltration on the same filter. The cytotoxin is concentrated approximately 500 fold, and remains active after 5 months of freezing. A vaccine trial for toxicity and efficacy were performed.